Developer docs
API playgroundTry for free, no card

Search company profiles

STAQ Pharma

Full company profile

uuid000228q

Namestring
STAQ Pharma
Legal namestring
STAQ Pharma, Inc.
Websiteurl
staqpharma.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

STAQ Pharma, Inc. is a privately held, hospital-owned FDA-registered 503B outsourcing facility headquartered in Denver, Colorado. Founded in 2017/2018, the company produces ready-to-administer sterile compounded medications — pre-filled syringes, IV bags, nasal sprays, and Closed System Transfer Device (CSTD) kits — for hospitals, integrated health systems, ambulatory surgery centers, and pharmaceutical partners nationwide. Its core technology platform is cGMP-compliant sterile compounding executed through advanced semi-automation systems and a Master Control-based Quality Management System, with two purpose-built facilities in Denver (27,000+ sq ft, ~30,000 units/month) and Columbus, Ohio (approximately five times the Denver footprint, including dedicated hazardous drug capacity for oncology production launched in July 2024).

STAQ's products address critical drug shortages, pediatric formulation gaps, and hazardous drug handling requirements — categories where domestic cGMP-compliant supply has been chronically constrained. Its revenue model is transaction-based B2B sales of compounded sterile pharmaceuticals, augmented by professional services revenue from contract manufacturing partnerships with biopharma sponsors (e.g., IAVI/SK bioscience for an intranasal COVID-19 candidate, Cessatech for pediatric pain drug CT001). Distribution runs through a direct enterprise sales force, a secure online ordering portal, and Premier GPO contracts where the company doubled business over the prior year.

STAQ's ownership and governance structure is a defining feature: approximately eight major U.S. health systems — including Froedtert Health, UNC Health, LCMC Health, University Hospitals, Cincinnati Children's, Children's Hospital Colorado, Yale New Haven Health, and ThedaCare — hold equity and board seats, with a Product Development Committee of hospital pharmacy leaders guiding the product roadmap. This embedded customer-ownership model, combined with partnerships with the FDA, Children's Hospital Association, and Angels for Change under Project PROTECT, institutionalizes STAQ as a domestic shortage-response platform serving over 500,000 pediatric patients in the first six months of one program.

Short descriptiontext

STAQ Pharma is a hospital-owned FDA-registered 503B outsourcing facility that produces ready-to-administer sterile compounded medications — syringes, IV bags, nasal sprays, and CSTD kits — for hospitals, health systems, and biopharma partners across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
503B outsourcing facility, sterile compounded medications, hospital pharmacy supply, pharmaceutical contract manufacturing, hazardous drug handling
Industry2 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Sterile Compounded Pharmaceuticals (503B Outsourcing)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Compounded Sterile Pharmaceutical Products
TypeTransaction Fee
Description

STAQ Pharma generates revenue through the sale of FDA-registered 503B compounded sterile medications including syringes, IV bags, nasal sprays, and CSTD kits. Products are sold directly to hospitals, healthcare systems, and ambulatory surgery centers nationwide.

staqpharma.com
2Contract Manufacturing Services
TypeProfessional Services
Description

Provides fill-finish contract manufacturing services for pharmaceutical partners, including production of intranasal sprays and other drug products for collaborators like IAVI and SK bioscience.

premierinc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Direct purchase model for healthcare facilities
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Orders placed through online portal or direct sales contact. No public pricing available - quote-based system.

staqpharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

STAQ Pharma is an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-administer sterile compounded medications—pre-filled syringes, IV bags, nasal sprays, and Closed System Transfer Device (CSTD) kits—to U.S. hospitals, health systems, and ambulatory surgery centers. Production is concentrated on medications affected by critical drug shortages, including pediatric formulations and hazardous oncology drugs, and is performed under cGMP standards across two purpose-built facilities in Denver, CO and Columbus, OH.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 500,000 pediatric patients protected from drug shortages of Potassium Chloride and Sodium Chloride in first 6 months of partnership with Angels for Change
+2 more records
Product overview1 text field

STAQ Pharma operates as a 503B outsourcing facility offering a comprehensive portfolio of sterile compounded medications. The company produces four main product lines: pre-filled syringes (opioids, anesthetics, sedatives, critical care medications), sterile IV bags (pain management, vasopressors), nasal sprays (Desmopressin Acetate), and CSTD kits for hazardous drug handling (Methotrexate). Their Columbus, Ohio facility is specifically designed for oncology drug production. Products address critical drug shortages for hospitals and healthcare systems nationwide, with a focus on pediatric and hospital-specific dosing needs.

Product and service7 records
1Sterile Compounded Syringes
CategorySterile Compounded Injectables
Description

Pre-filled sterile syringes in various dosages covering opioids (fentanyl, hydromorphone, morphine), anesthetics (ketamine, lidocaine), sedatives (midazolam, dexmedetomidine), and critical care medications (phenylephrine, epinephrine, atropine), sold to hospitals and health systems for direct administration.

2Sterile Compounded IV Bags
CategorySterile Compounded Injectables
Description

Ready-to-use sterile IV bags containing pain management medications (ketamine, fentanyl, hydromorphone, ropivacaine) and vasopressors (phenylephrine) in various concentrations and volumes, sold to hospitals and health systems.

3Sterile Compounded Nasal Sprays
CategorySterile Compounded Specialty Dosage Forms
Description

Sterile nasal spray formulations including Desmopressin Acetate for desmopressin therapy, sold to hospitals and health systems for patient administration.

4Methotrexate PF CSTD Kit
CategoryHazardous / Oncology Compounded Injectables
Description

Closed System Transfer Device (CSTD) kit for hazardous oncology drug handling, containing Methotrexate 25 mg/mL in a 5 mL syringe with ICU Medical Spinning Spiros adaptor, waste syringe, transfer set, and hazardous waste bag.

5Albuterol Sulfate Inhalation Solution
CategorySterile Compounded Respiratory / Inhalation Products
Description

Pre-filled syringes of Albuterol 0.5% inhalation solution (preservative-free) in 15 mg/3 mL and 100 mg/20 mL concentrations for respiratory treatment, sold to hospitals and pediatric facilities.

6Oncology Portfolio
CategoryHazardous / Oncology Compounded Injectables
Description

Sterile compounded oncology medications including methotrexate, produced in a dedicated hazardous drug facility (Columbus, OH) designed specifically for cancer drug production and sold to hospitals and cancer treatment centers.

7Pharmaceutical Contract Manufacturing Services
CategoryPharmaceutical Contract Manufacturing
Description

Fill-finish contract manufacturing services for pharmaceutical and biotechnology partners, including production of intranasal sprays and other sterile drug products, leveraging STAQ Pharma's cGMP facilities, semi-automation, and hazardous drug capabilities.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-08
Description

Partnership through Premier's 503B Pharmacy Compounding Services GPO program. STAQ Pharma doubled its Premier GPO business over the past year. Partnership addresses compounding challenges including drug shortages, regulatory compliance, and supply chain transparency.

2Angels for Change
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-07
Description

Nonprofit organization addressing drug shortages through supply chain innovation. Partnership under Project PROTECT to increase domestic manufacturing of critical medicines including Magnesium Sulfate IV bags. Over 500,000 pediatric patients protected from shortages through this partnership.

einpresswire.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-31
Description

Danish pediatric biotech company collaborating with STAQ Pharma for production of CT001, a pediatric acute pain management drug. STAQ Pharma and Ventis Pharma collaborating to bring the product to US hospitals.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-01-08
Description

Nonprofit scientific research organization. STAQ Pharma providing support services for production of innovative intranasal spray (IPD-52520) targeting COVID-19. Multi-partner project with SK bioscience and University of Washington's Institute for Protein Design.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-01-08
Description

South Korean biotech company collaborating on development of intranasal COVID-19 spray (IPD-52520) with STAQ Pharma handling fill-finish operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Regulatory partnership with FDA to address albuterol shortage. STAQ Pharma working with FDA and Children's Hospital Association to maintain supply of critical respiratory medications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership with Children's Hospital Association to address critical drug shortages. Multiple collaborative initiatives including albuterol shortage response and Project PROTECT.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership to supply and maintain continuous albuterol for children's hospitals, addressing pediatric respiratory medication shortages since June 2022.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Wells Pharma is an FDA-registered 503B outsourcing facility providing sterile compounded medications to hospitals and surgery centers nationwide. It competes with STAQ in sterile injectable outsourcing with similar product categories and customer base.

TypeRegional player
Description

Equashield is a manufacturer of closed system transfer devices (CSTDs) for hazardous drug handling, complementary to STAQ's methotrexate CSTD kit. While not a direct compounder, it represents the supplier ecosystem STAQ integrates with for its hazardous drug product line and a potential partner/competitor in the oncology compounding value chain.

TypeOthers
Description

ICU Medical supplies the Spinning Spiros CSTD adaptor used in STAQ's methotrexate kit and broader closed-system drug transfer infrastructure. As a medical device supplier in the oncology and hazardous drug handling category that STAQ serves, ICU Medical is a key component partner and adjacent player in the same hospital pharmacy workflow.

TypeDirect peer
Description

QuVa Pharma is one of the largest FDA-registered 503B outsourcing facilities in the U.S., producing sterile compounded ready-to-administer medications for hospitals. It is the most direct competitor to STAQ in sterile injectable compounding, with similar customer base (hospitals/health systems), similar product formats (pre-filled syringes, IV bags), and similar regulatory positioning.

TypeBroad incumbent
Description

Catalent is a large global CDMO providing sterile fill-finish and manufacturing services for injectable drug products. As STAQ expands into CDMO services (e.g., for IAVI, Cessatech), Catalent represents a much larger incumbent in the contract sterile injectable manufacturing space that STAQ competes against for biopharma partnerships.

TypeBroad incumbent
Description

Thermo Fisher, through its Patheon pharma services business, is a global CDMO leader in sterile injectable manufacturing. It represents a larger incumbent competing for CDMO contracts in the same fill-finish and clinical supply categories that STAQ's CDMO services target.

TypeDirect peer
Description

Fagron operates 503B-registered sterile compounding outsourcing facilities serving hospitals and health systems across the U.S. It is a direct competitor to STAQ in sterile injectable outsourcing, with overlapping product categories (pre-filled syringes, IV bags) and hospital customer base.

TypeOthers
Description

Premier Inc. is a healthcare performance improvement company and major GPO whose 503B Pharmacy Compounding Services program STAQ participates in. Premier is a channel partner rather than a competitor, but its compounding services portfolio creates an indirect benchmark and potential competitor if Premier expands into direct sourcing or contracting with competing 503B facilities.

TypeEmerging player
Description

Civica Rx is a nonprofit generic drug company established by hospital systems to address drug shortages and supply chain vulnerabilities. While Civica is a manufacturer rather than a 503B compounder, it shares STAQ's mission of addressing essential drug shortages through domestic, hospital-backed manufacturing and competes for the same hospital procurement budget.

TypeDirect peer
Description

Leiters (formerly Leiters Compounding) is an FDA-registered 503B outsourcing facility producing sterile compounded preparations for hospital pharmacies. It competes head-to-head with STAQ in pre-filled syringes and IV bags, with overlapping customer types and similar emphasis on cGMP quality and ready-to-use formats.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STAQ Pharma

Sterile Compounded Pharmaceuticals (503B Outsourcing)staqpharma.com

STAQ Pharma is a hospital-owned FDA-registered 503B outsourcing facility that produces ready-to-administer sterile compounded medications — syringes, IV bags, nasal sprays, and CSTD kits — for hospitals, health systems, and biopharma partners across the United States.

What STAQ Pharma does

STAQ Pharma, Inc. is a privately held, hospital-owned FDA-registered 503B outsourcing facility headquartered in Denver, Colorado. Founded in 2017/2018, the company produces ready-to-administer sterile compounded medications — pre-filled syringes, IV bags, nasal sprays, and Closed System Transfer Device (CSTD) kits — for hospitals, integrated health systems, ambulatory surgery centers, and pharmaceutical partners nationwide. Its core technology platform is cGMP-compliant sterile compounding executed through advanced semi-automation systems and a Master Control-based Quality Management System, with two purpose-built facilities in Denver (27,000+ sq ft, ~30,000 units/month) and Columbus, Ohio (approximately five times the Denver footprint, including dedicated hazardous drug capacity for oncology production launched in July 2024).

STAQ's products address critical drug shortages, pediatric formulation gaps, and hazardous drug handling requirements — categories where domestic cGMP-compliant supply has been chronically constrained. Its revenue model is transaction-based B2B sales of compounded sterile pharmaceuticals, augmented by professional services revenue from contract manufacturing partnerships with biopharma sponsors (e.g., IAVI/SK bioscience for an intranasal COVID-19 candidate, Cessatech for pediatric pain drug CT001). Distribution runs through a direct enterprise sales force, a secure online ordering portal, and Premier GPO contracts where the company doubled business over the prior year.

STAQ's ownership and governance structure is a defining feature: approximately eight major U.S. health systems — including Froedtert Health, UNC Health, LCMC Health, University Hospitals, Cincinnati Children's, Children's Hospital Colorado, Yale New Haven Health, and ThedaCare — hold equity and board seats, with a Product Development Committee of hospital pharmacy leaders guiding the product roadmap. This embedded customer-ownership model, combined with partnerships with the FDA, Children's Hospital Association, and Angels for Change under Project PROTECT, institutionalizes STAQ as a domestic shortage-response platform serving over 500,000 pediatric patients in the first six months of one program.

STAQ Pharma firmographics

Firmographics
Name
STAQ Pharma
Legal name
STAQ Pharma, Inc.
Website
https://staqpharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
STAQ Pharma is a hospital-owned FDA-registered 503B outsourcing facility that produces ready-to-administer sterile compounded medications — syringes, IV bags, nasal sprays, and CSTD kits — for hospitals, health systems, and biopharma partners across the United States.
Ownership category
akta.pro rank

STAQ Pharma industry classification

Industry
Product category
Sterile Compounded Pharmaceuticals (503B Outsourcing)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • 503B outsourcing facility
  • Sterile compounded medications
  • Hospital pharmacy supply
  • Pharmaceutical contract manufacturing
  • Hazardous drug handling

Where STAQ Pharma is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices2 records

Markets served

STAQ Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Compounded Sterile Pharmaceutical Products: STAQ Pharma generates revenue through the sale of FDA-registered 503B compounded sterile medications including syringes, IV bags, nasal sprays, and CSTD kits. Products are sold directly to hospitals, healthcare systems, and ambulatory surgery centers nationwide.
  2. Contract Manufacturing Services: Provides fill-finish contract manufacturing services for pharmaceutical partners, including production of intranasal sprays and other drug products for collaborators like IAVI and SK bioscience.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goDirect purchase model for healthcare facilities

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

STAQ Pharma product offering

Product offering

Core offering

STAQ Pharma is an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-administer sterile compounded medications—pre-filled syringes, IV bags, nasal sprays, and Closed System Transfer Device (CSTD) kits—to U.S. hospitals, health systems, and ambulatory surgery centers. Production is concentrated on medications affected by critical drug shortages, including pediatric formulations and hazardous oncology drugs, and is performed under cGMP standards across two purpose-built facilities in Denver, CO and Columbus, OH.

Product overview

STAQ Pharma operates as a 503B outsourcing facility offering a comprehensive portfolio of sterile compounded medications. The company produces four main product lines: pre-filled syringes (opioids, anesthetics, sedatives, critical care medications), sterile IV bags (pain management, vasopressors), nasal sprays (Desmopressin Acetate), and CSTD kits for hazardous drug handling (Methotrexate). Their Columbus, Ohio facility is specifically designed for oncology drug production. Products address critical drug shortages for hospitals and healthcare systems nationwide, with a focus on pediatric and hospital-specific dosing needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sterile Compounded Syringes Pre-filled sterile syringes in various dosages covering opioids (fentanyl, hydromorphone, morphine), anesthetics (ketamine, lidocaine), sedatives (midazolam, dexmedetomidine), and critical care medications (phenylephrine, epinephrine, atropine), sold to hospitals and health systems for direct administration.
  • Sterile Compounded IV Bags Ready-to-use sterile IV bags containing pain management medications (ketamine, fentanyl, hydromorphone, ropivacaine) and vasopressors (phenylephrine) in various concentrations and volumes, sold to hospitals and health systems.
  • Sterile Compounded Nasal Sprays Sterile nasal spray formulations including Desmopressin Acetate for desmopressin therapy, sold to hospitals and health systems for patient administration.
  • Methotrexate PF CSTD Kit Closed System Transfer Device (CSTD) kit for hazardous oncology drug handling, containing Methotrexate 25 mg/mL in a 5 mL syringe with ICU Medical Spinning Spiros adaptor, waste syringe, transfer set, and hazardous waste bag.
  • Albuterol Sulfate Inhalation Solution Pre-filled syringes of Albuterol 0.5% inhalation solution (preservative-free) in 15 mg/3 mL and 100 mg/20 mL concentrations for respiratory treatment, sold to hospitals and pediatric facilities.
  • Oncology Portfolio Sterile compounded oncology medications including methotrexate, produced in a dedicated hazardous drug facility (Columbus, OH) designed specifically for cancer drug production and sold to hospitals and cancer treatment centers.
  • Pharmaceutical Contract Manufacturing Services Fill-finish contract manufacturing services for pharmaceutical and biotechnology partners, including production of intranasal sprays and other sterile drug products, leveraging STAQ Pharma's cGMP facilities, semi-automation, and hazardous drug capabilities.

Quantifiable outcome

  • Over 500,000 pediatric patients protected from drug shortages of Potassium Chloride and Sodium Chloride in first 6 months of partnership with Angels for Change
  • +2 more outcomes

Companies that use STAQ Pharma

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

STAQ Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

STAQ Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and strategic.

  • Premier Inc.coreChannel Partner/ Reseller/ Distributor · 8 January 2026Partnership through Premier's 503B Pharmacy Compounding Services GPO program. STAQ Pharma doubled its Premier GPO business over the past year. Partnership addresses compounding challenges including drug shortages, regulatory compliance, and supply chain transparency.
  • Angels for ChangecoreStrategic or Co-development Partner · 7 November 2025Nonprofit organization addressing drug shortages through supply chain innovation. Partnership under Project PROTECT to increase domestic manufacturing of critical medicines including Magnesium Sulfate IV bags. Over 500,000 pediatric patients protected from shortages through this partnership.
  • CessatechstrategicStrategic or Co-development Partner · 31 October 2025Danish pediatric biotech company collaborating with STAQ Pharma for production of CT001, a pediatric acute pain management drug. STAQ Pharma and Ventis Pharma collaborating to bring the product to US hospitals.
  • IAVIstrategicStrategic or Co-development Partner · 8 January 2024Nonprofit scientific research organization. STAQ Pharma providing support services for production of innovative intranasal spray (IPD-52520) targeting COVID-19. Multi-partner project with SK bioscience and University of Washington's Institute for Protein Design.
  • SK biosciencestrategicStrategic or Co-development Partner · 8 January 2024South Korean biotech company collaborating on development of intranasal COVID-19 spray (IPD-52520) with STAQ Pharma handling fill-finish operations.
  • FDAcoreStrategic or Co-development Partner · 1 January 2023Regulatory partnership with FDA to address albuterol shortage. STAQ Pharma working with FDA and Children's Hospital Association to maintain supply of critical respiratory medications.
  • Children's Hospital AssociationcoreStrategic or Co-development Partner · 1 January 2023Partnership with Children's Hospital Association to address critical drug shortages. Multiple collaborative initiatives including albuterol shortage response and Project PROTECT.
  • Children's Hospital ColoradocoreStrategic or Co-development Partner · 1 January 2023Partnership to supply and maintain continuous albuterol for children's hospitals, addressing pediatric respiratory medication shortages since June 2022.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

STAQ Pharma competitors and assessment

Company assessment

Direct peers

  • Wells Pharma of Houston: Wells Pharma is an FDA-registered 503B outsourcing facility providing sterile compounded medications to hospitals and surgery centers nationwide. It competes with STAQ in sterile injectable outsourcing with similar product categories and customer base.
  • QuVa Pharma: QuVa Pharma is one of the largest FDA-registered 503B outsourcing facilities in the U.S., producing sterile compounded ready-to-administer medications for hospitals. It is the most direct competitor to STAQ in sterile injectable compounding, with similar customer base (hospitals/health systems), similar product formats (pre-filled syringes, IV bags), and similar regulatory positioning.
  • Fagron Sterile Services: Fagron operates 503B-registered sterile compounding outsourcing facilities serving hospitals and health systems across the U.S. It is a direct competitor to STAQ in sterile injectable outsourcing, with overlapping product categories (pre-filled syringes, IV bags) and hospital customer base.
  • Leiters Health: Leiters (formerly Leiters Compounding) is an FDA-registered 503B outsourcing facility producing sterile compounded preparations for hospital pharmacies. It competes head-to-head with STAQ in pre-filled syringes and IV bags, with overlapping customer types and similar emphasis on cGMP quality and ready-to-use formats.

Regional players

  • Equashield: Equashield is a manufacturer of closed system transfer devices (CSTDs) for hazardous drug handling, complementary to STAQ's methotrexate CSTD kit. While not a direct compounder, it represents the supplier ecosystem STAQ integrates with for its hazardous drug product line and a potential partner/competitor in the oncology compounding value chain.

Others

  • ICU Medical: ICU Medical supplies the Spinning Spiros CSTD adaptor used in STAQ's methotrexate kit and broader closed-system drug transfer infrastructure. As a medical device supplier in the oncology and hazardous drug handling category that STAQ serves, ICU Medical is a key component partner and adjacent player in the same hospital pharmacy workflow.
  • Premier Inc. Premier Inc. is a healthcare performance improvement company and major GPO whose 503B Pharmacy Compounding Services program STAQ participates in. Premier is a channel partner rather than a competitor, but its compounding services portfolio creates an indirect benchmark and potential competitor if Premier expands into direct sourcing or contracting with competing 503B facilities.

Broad incumbents

  • Catalent: Catalent is a large global CDMO providing sterile fill-finish and manufacturing services for injectable drug products. As STAQ expands into CDMO services (e.g., for IAVI, Cessatech), Catalent represents a much larger incumbent in the contract sterile injectable manufacturing space that STAQ competes against for biopharma partnerships.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher, through its Patheon pharma services business, is a global CDMO leader in sterile injectable manufacturing. It represents a larger incumbent competing for CDMO contracts in the same fill-finish and clinical supply categories that STAQ's CDMO services target.

Emerging players

  • Civica Rx: Civica Rx is a nonprofit generic drug company established by hospital systems to address drug shortages and supply chain vulnerabilities. While Civica is a manufacturer rather than a 503B compounder, it shares STAQ's mission of addressing essential drug shortages through domestic, hospital-backed manufacturing and competes for the same hospital procurement budget.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

STAQ Pharma social profiles

Digital presence

STAQ Pharma compliance and trust

Trust signal

Compliance2 records

STAQ Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STAQ Pharma leadership team

Management profile

Number of profiles

Profiles9 records

STAQ Pharma funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STAQ Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STAQ Pharma

What does STAQ Pharma do?

STAQ Pharma is an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-administer sterile compounded medications—pre-filled syringes, IV bags, nasal sprays, and Closed System Transfer Device (CSTD) kits—to U.S. hospitals, health systems, and ambulatory surgery centers. Production is concentrated on medications affected by critical drug shortages, including pediatric formulations and hazardous oncology drugs, and is performed under cGMP standards across two purpose-built facilities in Denver, CO and Columbus, OH.

Is STAQ Pharma a public or private company?

STAQ Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was STAQ Pharma founded?

STAQ Pharma was founded in 2018. It employs 101 to 250 people.

Where is STAQ Pharma based?

STAQ Pharma is headquartered in Denver, United States, in the North America region.

How does STAQ Pharma make money?

Two revenue lines are on record. Compounded Sterile Pharmaceutical Products are the primary driver. The others are contract Manufacturing Services.

Who are STAQ Pharma's main competitors?

Direct peers on record are Wells Pharma of Houston, QuVa Pharma, Fagron Sterile Services and Leiters Health. Equashield is listed as a regional player. Others are ICU Medical and Premier Inc.. Broad incumbents are Catalent and Thermo Fisher Scientific (Patheon). Civica Rx is listed as an emerging player.

Does STAQ Pharma have an API?

No public API is recorded for STAQ Pharma.

What industry is STAQ Pharma in?

STAQ Pharma's product category is Sterile Compounded Pharmaceuticals (503B Outsourcing). Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comCT001 ready for shipment to initial U.S. hospitals as launch activities commenceCessatech announced the release of CT001 by its U.S. partner STAQ Pharma, making the nasal spray available for shipment to initial U.S. hospitals. The first commercial batch marks an operational milestone, enabling launch activities with selected hospitals. The product targets acute moderate to severe pain in children aged 1-17.Managed Healthcare ExecutiveSupplies of Critical Nasal Spray for Hemophilia A, von Willebrand Disease Restored, but Patients and Coverage RecedeFerring Pharmaceuticals has suspended production of desmopressin nasal sprays for hemophilia A and von Willebrand disease due to packaging defects, leading STAQ Pharma to supply alternative vials since 2021. Despite being $80 cheaper per vial than the original product, STAQ's spray faces significant reimbursement challenges from payers and pharmacy benefit managers. Consequently, many patients have switched to more costly intravenous clotting factors or subcutaneous injections, reducing market access despite restored physical availability.news.cision.comWelcome to the first quarter of 2026Cessatech, a Danish pediatric biotech company, issued a first-quarter 2026 shareholder update reviewing 2025 progress and outlining plans for its lead product CT001, a pediatric acute pain treatment. Key regulatory milestones include a positive MDR opinion received and a Marketing Authorisation Application submitted to the European Medicines Agency, while US launch preparations are advancing with manufacturing partner STAQ Pharma completing development batches and stability studies underway. The company also announced new CT001 patents secured in the US and Asia-Pacific, and a new Senior Director of Finance & Investor Relations hired in November 2025.EIN PresswireProject PROTECT Milestone: Angels for Change and STAQ Pharma Strengthen U.S. Supply of Magnesium SulfateAngels for Change announced that STAQ Pharma, a hospital-owned 503B outsourcing facility and recipient of a 2025 Project PROTECT grant, has completed the Preparation and Protective phases for Magnesium Sulfate IV bag production, with readiness scheduled for December 1, 2025. Magnesium Sulfate is a critical lifesaving medication frequently appearing on national drug shortage lists, used for treating severe asthma attacks, eclampsia, pre-eclampsia, and cardiac emergencies. Project PROTECT, launched in 2022, has already ensured over 750,000 patient treatments during three national shortages by building U.S. manufacturing capacity for essential medicines at risk of shortage.news.cision.comCT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in childrenCessatech A/S announced the successful completion of technology transfer of CT001 with manufacturing partner STAQ Pharma, marking a significant step toward making the analgesic nasal spray available to US hospitals for acute pain management in children. The product is expected to reach the first US hospitals within the coming months as marketing and training materials are finalized. In parallel, CT001 is under evaluation by the European Medicines Agency through a Paediatric-Use Marketing Authorisation application for pediatric use.ChildrenshospitalsCreating a New Supply Chain for Continuous AlbuterolSTAQ Pharma began manufacturing continuous albuterol to address a critical shortage affecting children's hospitals in the U.S. following the suspension of production by existing commercial suppliers. The Children’s Hospital Association facilitated this solution by coordinating with STAQ to secure active pharmaceutical ingredients and navigating regulatory pathways with the FDA.SecSEC FORM DSTAQ Pharma, Inc. filed a Form D with the SEC on September 12, 2024, announcing an exempt offering of equity securities under Rule 506(b). The company has raised $11,400,001 out of a total offering amount of $30,000,000 from eight investors since the first sale on September 4, 2024.The Columbus DispatchAs drug shortages abound, Columbus drug manufacturer steps up to make chemo drugs for kidsSTAQ Pharma, a Denver-based supplier, launched its oncology drugs portfolio at its Columbus location on Friday. The move aims to combat a national drug shortage and improve access to critical cancer medications for children.